In hepatocellular carcinoma, combined anti-CTLA-4 and PD-1 together with the HDACi Belinostat significantly reduced tumor burden; which was associated with increased IFNγ production by T cells, and decreased amounts of Treg (207). This evidence concerns the gene PDCD1 and neoplasm.